Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc.

2.16
USD
-0.14
(-6.09%)
-0.15EPS
374.62MMarket Cap
Mar 01Next Earn

Total Valuation

USD

As of June 30, 2026, Rocket Pharmaceuticals, Inc. carries a market capitalization of 374.62M, placing it among publicly traded companies globally. Its enterprise value stands at 115.68M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap374.62M
Enterprise Value115.68M

Important Dates

Rocket Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for March 1, 2027.

Earnings Date3/1/2027

Share Statistics

As of June 30, 2026, Rocket Pharmaceuticals, Inc. has 109.54M shares outstanding.

Shares Outstanding109.54M

Valuation Ratios

These figures are as of June 30, 2026.

PB Ratio1.02
P/TBV Ratio1.23
P/FCF Ratio-2.26
P/OCF Ratio-2.25

Financial Position

As of June 30, 2026, Rocket Pharmaceuticals, Inc. maintains a current ratio of 9.24, meaning it holds 9.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.72, indicating elevated leverage, while an interest coverage ratio of -96.16 demonstrates limited ability to service its debt obligations.

Current Ratio9.24
Quick Ratio9.06
Debt / Equity6.72
Debt / EBITDA-0.14
Interest Coverage-96.16

Financial Efficiency

Over the twelve months ended June 30, 2026, Rocket Pharmaceuticals, Inc. posted a negative return on equity (ROE) of -4.77, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -4.09, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 226.25, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-4.77
Return on Assets (ROA)-4.09
Employee Count226.25

Taxes

USD

Over the twelve months ended June 30, 2026, Rocket Pharmaceuticals, Inc. recorded 8.62M in income tax expense. The company reported a pretax loss of -8.63M and -17.25M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax8.62M

Stock Price Statistics

USD

As of the close on November 16, 2026, Rocket Pharmaceuticals, Inc.'s stock has declined approximately 29.18% over the past 52 weeks. The 50-day moving average sits at 2.68, while the 200-day moving average is 3.38.

52-Week Price Change-29.18%
50-Day Moving Average2.68
200-Day Moving Average3.38

Income Statement

USD

Over the twelve months ended June 30, 2026, Rocket Pharmaceuticals, Inc. generated - - in revenue and converted that into -17.25M in net income, yielding earnings per share of -0.15. EBITDA reached -181.94M, while operating income came in at -191.88M.

Operating Income-191.88M
Pretax Income-8.63M
Net Income-17.25M
EBITDA-181.94M
EBIT-191.64M
Earnings Per Share (EPS)-0.15

Balance Sheet

USD

As of June 30, 2026, Rocket Pharmaceuticals, Inc. holds 283.75M in cash and equivalents against 24.80M in total debt, resulting in a net debt position of -224.51M. Total book value stands at 368.83M, with working capital of 258.23M providing operational flexibility.

Cash & Cash Equivalents283.75M
Total Debt24.80M
Net Debt-224.51M
Equity (Book Value)368.83M
Book Value Per Share3.37
Working Capital258.23M

Cash Flow

USD

Rocket Pharmaceuticals, Inc. produced -170.27M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -127,000.00 in capital expenditures, free cash flow totaled -170.39M - equivalent to -1.52 per share.

Operating Cash Flow-170.27M
Capital Expenditures-127,000.00
Free Cash Flow-170.39M
FCF Per Share-1.52

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -44.29: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.02, meaning Rocket Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-0.02
FCF Yield-44.29

Stock Splits

Rocket Pharmaceuticals, Inc.'s most recent stock split took place on January 5, 2018 with a 4:1 split ratio.

Last Split Date1/5/2018
Split Ratio4:1

Scores

As of June 30, 2026, Rocket Pharmaceuticals, Inc. has an Altman Z-Score of -2.09, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-2.09